Common Problems in Psychedelic Science, and How to Fix Them
Psychedelic science appears to ignore many of the lessons learned from decades of research in other fields.
Scientific Evidence
-
Read more: Common Problems in Psychedelic Science, and How to Fix Them -
Read more: History Rhymes with the Psychedelic Boom History Rhymes with the Psychedelic Boom
As a historian of psychoactive pharmaceuticals in the 20th century U.S., I see history rhyming in potentially dangerous ways in the current psychedelic boom.
-
Read more: The Psychedelics Industry: Psychedelic Evangelism in Second Wave Research The Psychedelics Industry: Psychedelic Evangelism in Second Wave Research
Without committing to open science practices, we risk producing a psychedelics industry with the same efficacy and integrity as the self-help industry.
-
Read more: Psychedelics in the Clinical Setting: The Potential for Harm and the Promise of Healing Psychedelics in the Clinical Setting: The Potential for Harm and the Promise of Healing
There are a number of unique issues that psychedelics present in a clinical setting that are yet to be adequately addressed.
-
Read more: Introductory Editorial — Critical Psychedelic Studies: Correcting the Hype Introductory Editorial — Critical Psychedelic Studies: Correcting the Hype
As we move past a phase of “partial eclipse” by psychedelic hype, this critical field is finally well-situated to explore the full spectrum of psychedelic effects.
-
Read more: The SCOTUS Antibody Ruling Has an Uncertain Impact for Drug Makers and Patients The SCOTUS Antibody Ruling Has an Uncertain Impact for Drug Makers and Patients
Scholars, analysts, and companies cannot agree on what Amgen v. Sanofi means for patients, drug makers, and innovation.
-
Read more: When the Law of Scientific Evidence Collides with Medical Practice When the Law of Scientific Evidence Collides with Medical Practice
The calculus involved in revoking the shaken baby syndrome diagnosis needs careful evaluation.
-
Read more: The Privatization of Cancer The Privatization of Cancer
In my forthcoming article, I argue that our cancer regulatory regimes inadequately protect the public.
-
Read more: Organ Transplant Candidates Who Use Medical Cannabis Face Discrimination Organ Transplant Candidates Who Use Medical Cannabis Face Discrimination
Considering growing evidence that medical cannabis does not compromise post-transplant health outcomes, policymakers should rethink restrictions.
-
Read more: What the Law and Bioethics Tell Us About Synthetic Human Embryos What the Law and Bioethics Tell Us About Synthetic Human Embryos
A synthetic embryo can now be constructed without an egg or sperm. This throws a moral monkey-wrench into current restrictions on embryonic research.
